Asia Pacific Journal of Pediatric and Child Health

Abstract Ref Number = APCP173

Invited Speakers

Human Milk Oligosaccharides : natural vs. chemical engineered

Yulia Ariani,,, Damayanti Rusli Sjarif, Department of Pediatric, Faculty of medicine Universitas Indonesia, Jakarta Department of pediatric, Cipto Mangunkusumo Hospital, Jakarta Awal Bros Hospital, Bekasi

Background: Human Milk Oligosaccharides (HMOs) are unconjugated complex carbohydratesthat are highly abundant in human milk with lots of potential benefits. Recently chemical engineered HMOs are developed to enrich infant formula. Aim: Our aims were to discuss thevarious aspects of natural HMOsthrough a literature review, and then conduct a systematic review to assess the benefit ofadding chemical enginered HMOs into infant formula. Methods: Literature review was conducted by collecting articles covering HMOs within the last ten years. Systematic review results were summarized to illustrate the benefit of incorporatingchemical engineered HMOs into infant formula. Results: Literature review concluded some typical characteristics of natural HMOs that need to be considered in developing chemical engineered HMOs. Some of the characteristics are described as follow: HMOs have a considerable important roles toward infant health, oligosaccharidesamount and composition vary between women especially those are from different geographic origin, oligosaccharides also vary over the course of lactation,there are more than a hundred different HMOs have been identified yet not every woman synthesized the same set of oligosaccharides, genetic factor determine the set of oligosaccharides contained in human milk known as Se gene (secretory vs non-secretory) and Le gene (Le positive vs Le negative). Most of data that support this theory supportedfrom in vitro and animal studies. There is no clinical study support this findings yet. Recently there is one randomized clinical trial conducted, aimed to assess the benefit of adding 2’ fucosyllactose (2’FL) and lacto-N-neotetraose (LNnT) toward infant growth and morbidity which is warrant confirmation in future studies. There is still a big question mark whether non-secretory women who could not produce 2’ fucosyllactose need to be supplemented. Conclusions: there are still limited data about the complexity of biomechanism of natural HMOs and their role inside infants gut. There are lots of studies needed to be addressed regarding those important issues before it considered beneficial to be added into infant formula.

Keywords: Human Milk Oligosaccharide (HMO), natural, chemical engineered, breast milk, infant formula